Pharmacogenomics involves how an individual’s genomic make up can influence response to medicines. Pharmacogenomic testing provides an opportunity to tailor prescribing, to increase effectiveness and reduce the risk of adverse drug reactions.
NHS patients are already experiencing the benefits of pharmacogenomic testing in a number of indications:
- DPYD & fluoropyrimidines
- CYP2C19 & mavacamten (R454)
- TPMT/NUDT15 & thiopurines (M91.80 & M91.81)
- MT-RNR1 & Aminoglycosides (R65)
Click on each section to find out more about eligibility criteria and how to order a test.
Pharmacogenomics is set to play a key role in future healthcare, as set out in the NHS 10 Year Plan.
Further Pharmacogenomic Resources
UK pharmacogenomic dosing guidance
- Personalised medicine approach for fluoropyrimidine-based therapies – via link, Publications | UK SACT Board
International pharmacogenomic dosing guidance
- International pharmacogenomic dosing guidance – please visit:
- CPIC Guidelines – CPIC
Patient information
Educational resources
- GE notes pharmacogenomics –Introduction to pharmacogenomics — Knowledge Hub
- Genomics Education England Pharmacy and Genomics Genomics in Pharmacy – Genomics Education Programme
- Centre for Pharmacy PostGraduate Education
NHS Pharmacogenomics Network of Excellence
Newsletters
Download previous newsletters below: